Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
CRSP's Cash-to-Debt is ranked higher than
62% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. CRSP: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CRSP' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.07  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.65
CRSP's Equity-to-Asset is ranked lower than
51% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CRSP: 0.65 )
Ranked among companies with meaningful Equity-to-Asset only.
CRSP' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.22  Med: 0.56 Max: 0.68
Current: 0.65
-0.22
0.68
Interest Coverage No Debt
CRSP's Interest Coverage is ranked lower than
99.99% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CRSP: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CRSP' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Altman Z-Score: 4.35
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -805.36
CRSP's Operating Margin % is ranked lower than
77% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. CRSP: -805.36 )
Ranked among companies with meaningful Operating Margin % only.
CRSP' s Operating Margin % Range Over the Past 10 Years
Min: -10416.6  Med: -5867.97 Max: -805.36
Current: -805.36
-10416.6
-805.36
Net Margin % -406.47
CRSP's Net Margin % is ranked lower than
69% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. CRSP: -406.47 )
Ranked among companies with meaningful Net Margin % only.
CRSP' s Net Margin % Range Over the Past 10 Years
Min: -10325.1  Med: -5386.96 Max: -406.47
Current: -406.47
-10325.1
-406.47
ROE % -28.78
CRSP's ROE % is ranked higher than
52% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. CRSP: -28.78 )
Ranked among companies with meaningful ROE % only.
CRSP' s ROE % Range Over the Past 10 Years
Min: -28.78  Med: -22.75 Max: -22.75
Current: -28.78
-28.78
-22.75
ROA % -13.40
CRSP's ROA % is ranked higher than
64% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. CRSP: -13.40 )
Ranked among companies with meaningful ROA % only.
CRSP' s ROA % Range Over the Past 10 Years
Min: -410.22  Med: -31.69 Max: -9.19
Current: -13.4
-410.22
-9.19
ROC (Joel Greenblatt) % -290.93
CRSP's ROC (Joel Greenblatt) % is ranked higher than
50% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. CRSP: -290.93 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CRSP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3872.44  Med: -2001.84 Max: -131.23
Current: -290.93
-3872.44
-131.23
GuruFocus has detected 1 Warning Sign with CRISPR Therapeutics AG $CRSP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CRSP's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

CRSP Guru Trades in

CRSP Guru Trades in

Q1 2017

CRSP Guru Trades in Q1 2017

John Paulson 50,500 sh (New)
» More
Q2 2017

CRSP Guru Trades in Q2 2017

John Paulson 28,500 sh (-43.56%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:CRSP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2017-06-30 Reduce -43.56%$13.62 - $21.77 $ 18.3711%28,500
John Paulson 2017-03-31 New Buy0.01%$14.78 - $23.73 $ 18.37-6%50,500
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology  
Compare:XSWX:HBMNE, XSWX:BSLN, XSWX:MOLN, XSWX:SANN, NAS:ACIU, XSWX:SFZN, NAS:OBSV, XPAR:GNRO, XSWX:EVE, XSWX:KURN, XSWX:ADXN, NAS:EARS, XSWX:RLF, OTCPK:MYMX, XSWX:IDIA, XSWX:GALE, XSWX:BION, XSWX:ATLN » details
Traded in other countries:1CG.Germany,
Headquarter Location:Switzerland
CRISPR Therapeutics AG is a gene editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics.

Ratios

vs
industry
vs
history
PB Ratio 3.72
CRSP's PB Ratio is ranked higher than
61% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. CRSP: 3.72 )
Ranked among companies with meaningful PB Ratio only.
CRSP' s PB Ratio Range Over the Past 10 Years
Min: 2.56  Med: 3.33 Max: 4.03
Current: 3.72
2.56
4.03
PS Ratio 71.71
CRSP's PS Ratio is ranked lower than
83% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. CRSP: 71.71 )
Ranked among companies with meaningful PS Ratio only.
CRSP' s PS Ratio Range Over the Past 10 Years
Min: 55.63  Med: 99.92 Max: 158.73
Current: 71.71
55.63
158.73
EV-to-EBIT -11.73
CRSP's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. CRSP: -11.73 )
Ranked among companies with meaningful EV-to-EBIT only.
CRSP' s EV-to-EBIT Range Over the Past 10 Years
Min: -39.5  Med: -12.85 Max: -7.3
Current: -11.73
-39.5
-7.3
EV-to-EBITDA -12.33
CRSP's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. CRSP: -12.33 )
Ranked among companies with meaningful EV-to-EBITDA only.
CRSP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -42.2  Med: -13.45 Max: -7.7
Current: -12.33
-42.2
-7.7
Current Ratio 17.79
CRSP's Current Ratio is ranked higher than
91% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. CRSP: 17.79 )
Ranked among companies with meaningful Current Ratio only.
CRSP' s Current Ratio Range Over the Past 10 Years
Min: 2.97  Med: 15 Max: 17.79
Current: 17.79
2.97
17.79
Quick Ratio 17.79
CRSP's Quick Ratio is ranked higher than
92% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. CRSP: 17.79 )
Ranked among companies with meaningful Quick Ratio only.
CRSP' s Quick Ratio Range Over the Past 10 Years
Min: 2.97  Med: 15 Max: 17.79
Current: 17.79
2.97
17.79
Days Sales Outstanding 196.31
CRSP's Days Sales Outstanding is ranked lower than
91% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. CRSP: 196.31 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRSP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 169.99  Med: 335.47 Max: 500.95
Current: 196.31
169.99
500.95

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 4.46
CRSP's Price-to-Net-Cash is ranked higher than
76% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. CRSP: 4.46 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CRSP' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.9  Med: 3.96 Max: 4.77
Current: 4.46
3.9
4.77
Price-to-Net-Current-Asset-Value 4.22
CRSP's Price-to-Net-Current-Asset-Value is ranked higher than
75% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. CRSP: 4.22 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CRSP' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.69  Med: 3.87 Max: 4.58
Current: 4.22
3.69
4.58
Price-to-Tangible-Book 3.73
CRSP's Price-to-Tangible-Book is ranked higher than
69% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. CRSP: 3.73 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CRSP' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.26  Med: 3.46 Max: 4.04
Current: 3.73
3.26
4.04
Price-to-Median-PS-Value 0.72
CRSP's Price-to-Median-PS-Value is ranked higher than
64% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. CRSP: 0.72 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CRSP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.63  Med: 1.17 Max: 1.43
Current: 0.72
0.63
1.43
Earnings Yield (Greenblatt) % -8.54
CRSP's Earnings Yield (Greenblatt) % is ranked lower than
56% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. CRSP: -8.54 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CRSP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -13.6  Med: -7.8 Max: -2.5
Current: -8.54
-13.6
-2.5

More Statistics

Revenue (TTM) (Mil) $10.18
EPS (TTM) $ -0.67
Short Percentage of Float3.21%
52-Week Range $11.63 - 25.00
Shares Outstanding (Mil)40.59

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 14 24 91
EPS ($) -2.44 -3.09 -2.72
EPS without NRI ($) -2.44 -3.09 -2.72
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CRSP

Headlines

Articles On GuruFocus.com
CRISPR Therapeutics Announces Second Quarter 2017 Financial Results and Provides Business Update Aug 10 2017 
CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appellate Jul 25 2017 
CRISPR Therapeutics and Neon Therapeutics Enter Research Collaboration Jul 10 2017 
CRISPR Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China Jun 19 2017 
CRISPR Therapeutics to Present at the JMP Securities Life Sciences Conference Jun 14 2017 
CRISPR Therapeutics Appoints James R. Kasinger as General Counsel Jun 07 2017 
CRISPR Therapeutics and MaSTherCell SA sign service agreement for the development and manufacturing Jun 06 2017 
CRISPR Therapeutics and collaborators at the University of Florida awarded Target ALS Grant to devel May 16 2017 
CRISPR Therapeutics to Present at Investor Conferences in May May 12 2017 
CRISPR Therapeutics Reports Financial Results for the Three Months Ended March 31, 2017 and Provides May 11 2017 

More From Other Websites
This Technology Could Make You Rich -- and Change the World As We Know It Aug 13 2017
CRISPR Therapeutics Announces Second Quarter 2017 Financial Results and Provides Business Update Aug 10 2017
CRISPR Therapeutics Appoints Dr. Tony W. Ho to Head Research & Development Aug 01 2017
CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appellate... Jul 25 2017
This Is Why Investors Will Need to Learn a New Acronym: CRISPR Jul 17 2017
Never Will I Ever Buy Preclinical Biotech Stocks. No Way! Jul 15 2017
Why You're Smart to Buy Vertex Pharmaceuticals Stock Jul 15 2017
Why CRISPR Therapeutics AG Jumped 11.7% in June Jul 10 2017
CRISPR Therapeutics and Neon Therapeutics Enter Research Collaboration Jul 10 2017
CRISPR Gene Editing Controversy: Does It Really Cause Unexpected Mutations? Jul 10 2017
3 Growth Stocks for Forward-Looking Investors Jul 09 2017
CRISPR Therapeutics to Present at the Piper Jaffray GenomeRx Symposium Jul 05 2017
CRISPR Therapeutics AG breached its 50 day moving average in a Bullish Manner : CRSP-US : June 23,... Jun 23 2017
CRISPR Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China Jun 19 2017
CRISPR Therapeutics to Present at the JMP Securities Life Sciences Conference Jun 14 2017
CRISPR Therapeutics Appoints James R. Kasinger as General Counsel Jun 07 2017
​Two gene editing firms unveil cancer drug pacts as ASCO comes to a close Jun 06 2017
CRISPR Therapeutics and MaSTherCell SA sign service agreement for the development and manufacturing... Jun 06 2017
CRISPR Therapeutics AG :CRSP-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Jun 02 2017
Here's Why Editas Medicine Fell as Much as 15.7% Today May 30 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}